ZyVersa Therapeutics, Inc.
ZVSA
$0.18
-$0.02-11.21%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.74M | 1.63M | 1.89M | 1.17M | 1.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10M | 2.04M | 2.14M | 1.29M | 2.27M |
| Operating Income | -2.10M | -2.04M | -2.14M | -1.29M | -2.27M |
| Income Before Tax | -20.66M | -2.21M | -2.26M | -1.42M | -2.40M |
| Income Tax Expenses | -851.70K | -- | -- | -3.00K | -- |
| Earnings from Continuing Operations | -19.81M | -2.21M | -2.26M | -1.42M | -2.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.81M | -2.21M | -2.26M | -1.42M | -2.40M |
| EBIT | -2.10M | -2.04M | -2.14M | -1.29M | -2.27M |
| EBITDA | -2.10M | -2.04M | -2.14M | -1.29M | -2.27M |
| EPS Basic | -2.56 | -0.46 | -0.73 | -0.71 | -2.43 |
| Normalized Basic EPS | -0.16 | -0.29 | -0.45 | -0.45 | -1.52 |
| EPS Diluted | -2.56 | -0.46 | -0.73 | -0.71 | -2.43 |
| Normalized Diluted EPS | -0.16 | -0.29 | -0.45 | -0.45 | -1.52 |
| Average Basic Shares Outstanding | 7.74M | 4.81M | 3.11M | 1.99M | 988.40K |
| Average Diluted Shares Outstanding | 7.74M | 4.81M | 3.11M | 1.99M | 988.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |